Free Trial

Great Point Partners LLC Buys New Stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM)

Eliem Therapeutics logo with Medical background

Great Point Partners LLC acquired a new position in Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 248,168 shares of the company's stock, valued at approximately $1,263,000. Eliem Therapeutics accounts for approximately 0.4% of Great Point Partners LLC's investment portfolio, making the stock its 28th biggest position. Great Point Partners LLC owned approximately 0.83% of Eliem Therapeutics at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Advantage Alpha Capital Partners LP bought a new position in shares of Eliem Therapeutics in the 3rd quarter worth about $245,000. The Manufacturers Life Insurance Company acquired a new stake in Eliem Therapeutics during the third quarter worth about $252,000. Valence8 US LP bought a new position in Eliem Therapeutics in the third quarter worth about $61,000. Charles Schwab Investment Management Inc. boosted its stake in Eliem Therapeutics by 309.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 70,093 shares of the company's stock valued at $357,000 after acquiring an additional 52,965 shares during the period. Finally, Segall Bryant & Hamill LLC acquired a new position in Eliem Therapeutics in the third quarter valued at approximately $297,000. Institutional investors own 69.76% of the company's stock.

Eliem Therapeutics Stock Performance

Shares of Eliem Therapeutics stock traded up $0.18 on Wednesday, reaching $3.22. 135,419 shares of the company were exchanged, compared to its average volume of 486,688. The firm has a market cap of $95.80 million, a price-to-earnings ratio of -5.74 and a beta of -0.39. Eliem Therapeutics, Inc. has a 1-year low of $2.35 and a 1-year high of $11.55. The company's 50-day moving average is $4.69 and its two-hundred day moving average is $6.49.

About Eliem Therapeutics

(Free Report)

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Further Reading

Institutional Ownership by Quarter for Eliem Therapeutics (NASDAQ:ELYM)

Should you invest $1,000 in Eliem Therapeutics right now?

Before you consider Eliem Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eliem Therapeutics wasn't on the list.

While Eliem Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?
SoundHound Stock Explodes Again – Is a Major Breakout Coming?
How Fintech Strategy at FinWise Bancorp and CEO Vision Are Driving 78% Gains

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines